Basit öğe kaydını göster

Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

dc.contributor.authorSerilmez, Murat
dc.contributor.authorKarabulut, Senem
dc.contributor.authorTas, Faruk
dc.contributor.authorDuranyildiz, Derya
dc.contributor.authorCiftci, Rumeysa
dc.date.accessioned2021-03-03T11:34:22Z
dc.date.available2021-03-03T11:34:22Z
dc.date.issued2014
dc.identifier.citationTas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D., "Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer", CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.73, sa.3, ss.631-637, 2014
dc.identifier.issn0344-5704
dc.identifier.othervv_1032021
dc.identifier.otherav_28ac9be5-26b3-4e11-b34f-a86afeef839a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/32189
dc.identifier.urihttps://doi.org/10.1007/s00280-014-2396-x
dc.description.abstractEpidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of multiple malignancies, and its expression also strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of EGFR in epithelial ovarian cancer (EOC) patients.
dc.language.isoeng
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectPharmacology (medical)
dc.subjectOncology
dc.subjectPharmacy
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectDrug Guides
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.titleIncreased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer
dc.typeMakale
dc.relation.journalCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume73
dc.identifier.issue3
dc.identifier.startpage631
dc.identifier.endpage637
dc.contributor.firstauthorID33506


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster